Mapping the landscape: a bibliometric study of global chimeric antigen receptor T cell immunotherapy research
- PMID: 38953967
- DOI: 10.1007/s00210-024-03258-6
Mapping the landscape: a bibliometric study of global chimeric antigen receptor T cell immunotherapy research
Abstract
The rise of immunotherapy provided new approaches to cancer treatment. We aimed to describe the contribution of chimeric antigen receptor T cell immunotherapy to future prospects. We analyzed 8035 articles from the Web of Science Core Collection with CiteSpace that covered with various aspects with countries, institutions, authors, co-cited authors, journals, keywords, and references. The USA was the most prolific country, with the University of Pennsylvania being the most published institution. Among individual authors, June Carl H published the most articles, while Maude SL was the most frequently co-cited author. "Blood" emerged as the most cited journal. Keyword clustering revealed six core themes: "Expression," "Chimeric Antigen Receptor," "Tumor Microenvironment," "Blinatumomab," "Multiple Myeloma," and "Cytokine Release Syndrome." In the process of researching the timeline chart of keywords and references, "Large B-cell lymphoma" was located on the right side of the timeline. In the keyword prominence analysis, we found that the keywords "biomarkers," "pd-1," "antibody drug conjugate," "BCMA," and "chimeric antigen" had high explosive intensity in the recent past. We found that in terms of related diseases, "large B-cell lymphoma" and "cytokine release syndrome" are still difficult problems in the future. In the study of therapeutic methods, "BCMA," "PD-1," "chimeric antigen," and "antibody drug conjugate" deserve more attention from researchers in the future.
Keywords: Bibliometric analysis; Cancer; Chimeric antigen receptor T cell immunotherapy; CiteSpace.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Ethical approval: No ethical approval was required for all analyses. Consent to participate: Informed consent was obtained from all individual participants included in the study. Consent for publication: The authors affirm that human research participants provided informed consent for publication. Competing interests: The authors declare no competing interests.
Similar articles
-
Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.Syst Rev. 2024 Nov 26;13(1):289. doi: 10.1186/s13643-024-02681-3. Syst Rev. 2024. PMID: 39593159 Free PMC article.
-
Big data analysis of endovascular treatment for acute ischemic stroke: a study based on bibliometric analysis.Arq Neuropsiquiatr. 2024 Oct;82(10):1-13. doi: 10.1055/s-0044-1789228. Epub 2024 Aug 31. Arq Neuropsiquiatr. 2024. PMID: 39216487 Free PMC article.
-
A Blog-Based Study of Autistic Adults' Experiences of Aloneness and Connection and the Interplay with Well-Being: Corpus-Based and Thematic Analyses.Autism Adulthood. 2023 Dec 1;5(4):437-449. doi: 10.1089/aut.2022.0073. Epub 2023 Dec 12. Autism Adulthood. 2023. PMID: 38116056 Free PMC article.
-
Pharmacological treatments in panic disorder in adults: a network meta-analysis.Cochrane Database Syst Rev. 2023 Nov 28;11(11):CD012729. doi: 10.1002/14651858.CD012729.pub3. Cochrane Database Syst Rev. 2023. PMID: 38014714 Free PMC article. Review.
-
Outcomes with chimeric antigen receptor T-cell therapy in Rheumatological disorders: A systematic review.Transpl Immunol. 2024 Dec;87:102137. doi: 10.1016/j.trim.2024.102137. Epub 2024 Oct 21. Transpl Immunol. 2024. PMID: 39442586 Review.
References
-
- Abbott M, Ustoyev Y (2019) Cancer and the immune system: the history and background of immunotherapy. Semin Oncol Nurs 35:150923. https://doi.org/10.1016/j.soncn.2019.08.002 - DOI - PubMed
-
- Alfouzan AF (2021) Radiation therapy in head and neck cancer. Saudi Med J 42:247–254. https://doi.org/10.15537/smj.2021.42.3.20210660 - DOI - PubMed - PMC
-
- Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, Beauvais D, Roulin L, Gros FX, Rubio MT, Bories P, Bay JO, Llorente CC, Choquet S, Casasnovas RO, Mohty M, Guidez S, Joris M, Loschi M, Carras S, Abraham J, Chauchet A, Drieu La Rochelle L, Deau-Fischer B, Hermine O, Gastinne T, Tudesq JJ, Gat E, Broussais F, Thieblemont C, Houot R, Morschhauser F (2022) A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med 28:2145–2154. https://doi.org/10.1038/s41591-022-01969-y - DOI - PubMed - PMC
-
- Baker DJ, Arany Z, Baur JA, Epstein JA, June CH (2023) CAR T therapy beyond cancer: the evolution of a living drug. Nature 619:707–715. https://doi.org/10.1038/s41586-023-06243-w - DOI - PubMed
-
- Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S (2019) Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci 20. https://doi.org/10.3390/ijms20061283
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous